chebulinic acid + chitosan + hyaluronic acid

Chebulinic acid + chitosan + hyaluronic acid is an experimental **nanoparticle-based anticancer formulation** in which the small molecule chebulinic acid is encapsulated within a chitosan matrix and surface-modified with hyaluronic acid to improve delivery to tumor cells. Based on the cited preclinical study, the formulation was designed for breast cancer therapy and showed greater in vitro cytotoxicity against MCF-7 breast cancer cells than free chebulinic acid, with supportive comet assay, flow-cytometry, and mouse tumor data. Its intended mechanism is not a single validated molecular target; rather, it functions as a **nanocarrier formulation** that enhances chebulinic acid delivery, cellular uptake, retention, and controlled release, while hyaluronic acid may facilitate tumor-directed interactions through HA-binding biology such as CD44-rich cancer cells. The available evidence appears preclinical and academic, with no clear commercial developer, brand name, or established clinical development program identified from the provided source.

Other names

CLA + CT + HACLA-CT-HA-NPshyaluronic acid modified chebulinic acid encapsulated chitosan nanocompositehyaluronic acid customized chebulinic acid chitosan hybrid nanoparticles